Latest news

The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the “Directed Issues”). The Directed Issues comprised a total of 34,203,780 shares, of which 31,603,780 shares have been partially registered during the month of March. The remaining 2,600,000

Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica’s equipment is unharmed. The initial assessment shows that none of Nanologica’s instruments or other equipment has been damaged, as water has only spread to Nanologica’s premises along the floor. The incident is under

Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of appx. SEK 82.5 million (the “Rights Issue”), for which the subscription period ended on 25 March 2026. The Rights Issue has been subscribed to 63.3 percent with and without the support of subscription rights, of which appx. 62.7 percent was subscribed for with the support of subscription rights and appx. 0.6 percent was subscribed for without the support

Teckningsperioden i Nanologicas företrädesemission inleds 11 mars och pågår till och med 25 mars. Teckning med stöd av företrädesrätt Teckning av aktier med stöd av teckningsrätter sker genom samtidig kontant betalning under perioden från och med den 11 mars 2026 till och med den 25 mars 2026. Observera att det kan ta upp till tre bankdagar för betalningen att nå mottagarkontot. Teckning och betalning ska ske i enlighet med något av nedanstående två alternativ. Emissionsredovisning

The nomination committee of Nanologica proposes to the Annual General Meeting on May 21 that Mark Quick and Erik Haeffler be elected as new members of the board of directors of Nanologica AB. Furthermore, Thomas Eldered is proposed as new chairman of the board. Mark Quick works as a Partner at Flerie AB having previously worked at Recipharm where he was Head of Corporate Development leading the M&A activities. Prior to that he held positions

Nanologica AB (publ) (”Nanologica” or ”the Company”) hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and allotted in accordance with the resolutions. Ardena Sweden AB has subscribed for and been allotted all 21,453,780 shares in the